Archive · 23 Jul 2026
Delhi High Court Raises Concerns Over HPV Vaccine Safety
The Delhi High Court is worried about the safety of the HPV vaccine Gardasil 9, which is being given to 14-year-old girls for free to prevent cervical cancer.
Some people, like Dr. Sujata Mittal and Jitendra Chouksey, say the vaccine has caused serious problems in the past, like deaths and autoimmune diseases.
They want the government to show data on any bad reactions from the vaccine.
The government and the World Health Organization (WHO) say the vaccine is safe and is used in many countries.
The court wants more information and will hear the case again on July 29.
The WHO says that more girls are getting the vaccine, but not enough to meet the goal of 90% coverage by 2030.
Delhi High Court expresses serious concerns over the safety of the HPV vaccine Gardasil 9.
Petitioners highlight past adverse events, including deaths and autoimmune ailments, and demand public data on adverse events.
The government and WHO maintain the vaccine is safe, citing extensive safety data and global usage.
The court requests the Ministry of Health and Family Welfare to provide data on adverse events.
The next court hearing is scheduled for July 29.
The WHO reports global HPV vaccine coverage at 33% in 2025, with a target of 90% by 2030.
- Who
- Delhi High Court, Petitioners (Dr. Sujata Mittal and Jitendra Chouksey), Government, WHO
- What
- Concerns over the safety and adverse events of the HPV vaccine Gardasil 9
- When
- Ongoing, with the next court hearing on July 29
- Where
- Delhi High Court, India
- Why
- To address safety concerns and ensure transparency in the HPV vaccine rollout
Petitioners' Concerns
Government and WHO Stance
Safety and Adverse Events
Petitioners' Concerns
Petitioners highlight past adverse events, including deaths and autoimmune ailments, and demand public data on adverse events.
Government and WHO Stance
The government and WHO maintain the vaccine is safe, citing extensive safety data and global usage.
Data Transparency
Petitioners' Concerns
Petitioners argue for robust, publicly available epidemiological assessments before mass vaccination.
Government and WHO Stance
The government has not publicly disclosed adverse event data, and the WHO reports incremental global coverage increases.
- Vaccine Name
- Gardasil 9
- Target Age Group
- 14-year-old girls
- Vaccine Type
- Quadrivalent HPV vaccine
- Global Coverage (2025)
- 33%
- Target Coverage by 2030
- 90%
- Countries Using HPV Vaccine (2025)
- 162
- Single-Dose Schedule Countries (2025)
- 93
- Next Court Hearing
- July 29
